Suicide Risk and Mood Disorders in Women in the Postpartum Period: a Longitudinal Study. de Avila Quevedo L, Scholl CC, de Matos MB, da Silva RA, da Cunha Coelho FM, Pinheiro KAT, Pinheiro RT. Psychiatr Q. 2020 Aug 18. The odds of postpartum suicide risk were 6.50 (95% CI: 2.73; 15.48) higher in mothers with… Read More »
Several articles from the Journal of Clinical Psychiatry report on suicidal and self-harm ideation in pregnant and postpartum women. Not surprisingly, a history of psychiatric illness increases risk; however, other factors play an important role, including history of self-harm and obstetric and neonatal complications. In this setting, we still do not know what drives women… Read More »
A Call to Action: Screening Fathers for Perinatal Depression. Walsh TB, Davis RN, Garfield C. Pediatrics. 2020 Jan;145(1). Preventing Postpartum Depression With Mindful Self-Compassion Intervention: A Randomized Control Study. Guo L, Zhang J, Mu L, Ye Z. J Nerv Ment Dis. 2019 Dec 18. Compared with the control group, the intervention group showed significant improvement… Read More »
The role of prenatal, obstetric, and post-partum factors in the parenting stress of mothers and fathers of 9-month old infants. Matvienko-Sikar K, Murphy G, Murphy M. J Psychosom Obstet Gynaecol. 2018 Mar;39(1):47-55. Mothers reported higher levels of parenting stress than fathers (p?<?0.001). Maternal parenting stress was predicted by attachment, own health status, average sleep, occupation,… Read More »
Preterm birth as a risk factor for postpartum depression: A systematic review and meta-analysis. de Paula Eduardo JAF, de Rezende MG, Menezes PR, Del-Ben CM. J Affect Disord. 2019 Aug 21;259:392-403. Most of the studies supported the association between preterm birth (PTB) and postpartum depression (PPD). However, 8 studies did not find such association and,… Read More »
Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies. Zheng W, Cai DB, Zheng W, Sim K, Ungvari GS, Peng XJ, Ning YP, Wang G, Xiang YT. Psychiatry Res. 2019 Jul 4;279:83-89. A single brexanolone infusion appears to have ultra-rapid antidepressant effect for PPD, lasting for up to 1 week. GABAAR Modulator for Postpartum… Read More »
The excitement over the FDA approval of brexanolone (to be marketed as Zulresso) is a good place to start this week’s roundup. Brexanolone is a derivative of the neurosteroid allopregnanolone, and, while Zulpresso was approved specifically for the treatment of postpartum depression, there is considerable research to indicate that the modulation of neurosteroid systems may… Read More »